Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 14/20 | 0.68 |
| ▸ | MGLL | Q99685 | 5/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4161521 | 0.82 | PARP10 (0.49) | HSD11B1MGLLGAA | |
| SCHEMBL6236172 | 0.81 | HSD11B1 (1.00) | HSD11B1MGLLKDM4EPOLBGAA | |
| SCHEMBL9785825 | 0.81 | HSD11B1 (0.56) | HSD11B1MGLLKDM4EPOLBGAA | |
| SCHEMBL9785783 | 0.79 | HSD11B1 (0.54) | HSD11B1MGLLKDM4EPOLBGAA | |
| SCHEMBL4158737 | 0.78 | RAB9A (0.56) | GAA | |
| SCHEMBL6210786 | 0.77 | HSD11B1 (0.73) | HSD11B1MGLL | |
| SCHEMBL27639508 | 0.76 | HSD11B1 (0.82) | HSD11B1MGLLPOLBGAA | |
| SCHEMBL9410535 | 0.76 | HSD11B1 (0.57) | HSD11B1MGLLKDM4EPOLBGAA | |
| SCHEMBL6348741 | 0.76 | HSD11B1 (1.00) | HSD11B1MGLL | |
| SCHEMBL1720014 | 0.76 | HSD11B1 (1.00) | HSD11B1MGLLKDM4EPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | claimed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | claimed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | claimed |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | disclosed |
| US-4990511-A | Amide compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-02-05 | — | — | US | disclosed |
| EP-0353753-A1 | Amide compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | HSD11B1, HSD3B1, P4HA1 | HSD11B1 1/4885MGLL 2824/4885KDM4E 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.